Leber Congenital Amaurosis (LCA) — the most severe early-onset inherited retinal dystrophy and the leading genetic cause of childhood blindness in the developed world, affecting approximately 2–3 per 100,000 live births and accounting for an estimated 5% of all inherited retinal dystrophies and up to 20% of cases of blindness in children attending schools for the blind, first described by Theodor Leber in 1869 as a distinct clinical entity characterized by severe visual impairment or blindness from birth or infancy, pendular nystagmus, and severely attenuated or extinguished electroretinographic responses — is a genetically heterogeneous autosomal recessive (and rarely autosomal dominant) retinal dystrophy caused by pathogenic variants in at least 27 confirmed genes (RPE65, GUCY2D, CEP290, RPGRIP1, AIPL1, CRB1, IMPDH1, CRX, LRAT, TULP1, RDH12, SPATA7, KCNJ13, NMNAT1, PRPH2, CLUAP1, IFT140, DTHD1, IQCB1, CNGA3, CNGB3, POC1B, ALMS1, CABP4, GDF6, OTX2, and KCNV2) encoding proteins essential to phototransduction, vitamin A metabolism in the retinal pigment epithelium, photoreceptor ciliary transport, photoreceptor structure, and retinal transcription factor signaling, with significant genotype-phenotype correlation informing both prognosis and treatment eligibility: RPE65-LCA, caused by biallelic variants in the gene encoding retinal pigment epithelium-specific 65 kDa protein that is essential to the visual cycle retinol isomerase activity converting all-trans-retinyl esters to 11-cis-retinol, is distinguished by preserved photoreceptor anatomy in early childhood despite severely impaired function and characteristic paradoxical pupillary response to light, and became the target of the first FDA-approved ocular gene therapy (voretigene neparvovec-rzyl, Luxturna, approved December 2017) administered as subretinal injection of AAV2-RPE65; CEP290-LCA, caused by the common deep intronic c.2991+1655A>G founder variant in CEP290 encoding a centrosomal protein critical to photoreceptor primary cilium formation and protein transport through the ciliary transition zone, presenting with severe early-onset visual impairment but variable photoreceptor preservation on imaging; GUCY2D-LCA, caused by gain-of-function dominant variants in retinal guanylate cyclase that lock photoreceptors in a constitutively activated state; and CRB1-LCA, associated with preservation of retinal thickness and a nummular pigmentation pattern. The clinical phenotype across LCA subtypes is defined by visual acuity typically hand motions or worse in early childhood, pendular nystagmus that develops within weeks of birth, absent or severely diminished photopupillary reflexes (oculodigital sign — compulsive eye pressing to generate phosphenes is pathognomonic), and severely attenuated or extinguished full-field ERG responses that distinguish LCA from other causes of poor visual behavior in infancy; additional features varying by genotype include high hyperopia (particularly in GUCY2D-LCA), intellectual disability (IQCB1-LCA), renal involvement (IQCB1/nephronophthisis-related ciliopathy), and liver involvement (ALMS1-LCA/Alström syndrome). The therapeutic landscape for LCA has been transformed by the approval of voretigene neparvovec for RPE65-LCA and by active gene therapy, antisense oligonucleotide (CEPT290 intronic variant correction), and CRISPR-based approaches targeting additional LCA genes in clinical trials, making molecular diagnosis, genotype-specific treatment eligibility assessment, and clinical trial enrollment coordination central to modern LCA management at specialized inherited retinal disease centers.
LCA technology platforms — whether supporting retinal dystrophy centers performing RPE65-LCA gene therapy with voretigene neparvovec (managing eligibility assessment records including biallelic RPE65 variant confirmation, baseline full-field ERG, multi-luminance mobility testing (MLMT) assessments, full-field stimulus testing (FST), optical coherence tomography retinal structure assessment, macular integrity documentation, and the surgical operative records for bilateral sequential subretinal voretigene neparvovec injection performed by vitreoretinal surgeons with sub-retinal delivery technique expertise); genetics and molecular diagnostics platforms managing LCA multi-gene panel sequencing (coordinating genetic testing for 27+ LCA genes, variant classification and pathogenicity interpretation, deep intronic variant identification using RNA analysis, clinical trial eligibility matching by gene, and genetic counseling for autosomal recessive inheritance with reproductive implications); clinical trial platforms enrolling LCA participants in CEP290 antisense oligonucleotide (sepofarsen), CRISPR correction, and additional gene therapy studies at specialized retinal dystrophy centers worldwide; ophthalmology and low vision platforms managing longitudinal retinal structure monitoring (OCT, fundus autofluorescence, adaptive optics), low vision assessment and device prescription, and orientation and mobility coordination for children with early-onset severe visual impairment; and pediatric and educational platforms managing vision rehabilitation, specialized education coordination with schools for the blind or visually impaired, and assistive technology — must maintain the availability and performance standards that gene therapy eligibility assessment, subretinal injection surgical coordination, molecular genetic reporting, and clinical trial enrollment demand. This guide explains why LCA tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the therapeutic, surgical, genetic, and rehabilitative complexity of modern LCA care.
Why LCA Tech Platforms Require Specialized Monitoring Attention
LCA management is defined by the unprecedented entry of approved gene therapy into pediatric retinal dystrophy practice — voretigene neparvovec for RPE65-LCA — and by a rapidly expanding pipeline of gene-specific therapies targeting CEP290, GUCY2D, and additional LCA genes in clinical trials, making the technology platforms supporting molecular diagnosis, gene therapy eligibility assessment, subretinal injection surgery, and post-treatment monitoring central to the care pathway in a way that has no parallel in other inherited retinal conditions. Technology failures in these domains create disruptions calibrated to the gene therapy surgical, eligibility assessment, molecular diagnostic, and post-treatment monitoring consequences of a condition where the treatment window may depend on preserving residual photoreceptor structure before degeneration eliminates the subretinal target cells.
Gene therapy eligibility assessment platforms are the gateway to approved treatment. RPE65-LCA gene therapy eligibility assessment — requiring platforms managing molecular confirmation of biallelic RPE65 pathogenic variants, full-field ERG amplitude documentation, multi-luminance mobility testing assessments documenting navigational ability under defined light levels, full-field stimulus testing (FST) sensitivity measurements, macular optical coherence tomography confirming viable photoreceptor cell layer thickness, macular integrity grading, and the specialist review that translates these measurements into FDA-required eligibility documentation for voretigene neparvovec — depends entirely on the platforms managing these measurements being available and reliable at the time of eligibility assessment. Monitor gene therapy eligibility platforms at 1-minute intervals during clinical sessions.
Vitreoretinal surgical planning platforms have critical impact during subretinal injection. Subretinal voretigene neparvovec delivery — where the vitreoretinal surgeon performing a 23-gauge pars plana vitrectomy creates a subretinal bleb via retinotomy to deliver 1.5 × 10¹¹ vector genomes in 0.3 mL balanced salt solution to the subretinal space of the target eye, where intraoperative OCT confirms subretinal bleb formation and distribution, where the second eye is operated after a minimum 6-day interval — depends on platforms managing operative documentation, informed consent confirmation, investigational product chain of custody records, intraoperative imaging integration, and post-operative retinal monitoring that must be reliably available throughout the operative and immediate post-operative period. Monitor surgical platforms at 1-minute intervals during operative sessions.
Molecular diagnostics platforms determine gene therapy and trial eligibility across 27 LCA genes. LCA molecular diagnosis requires accurate variant identification and classification across a 27-gene panel — including detection of the CEP290 deep intronic c.2991+1655A>G variant requiring long-read sequencing or targeted assays that are not captured by standard exome sequencing, identification of structural variants in genes like CRB1, and RNA functional analysis for intronic variants of uncertain significance — where delays in molecular reporting delay gene therapy eligibility confirmation, trial enrollment, and genotype-specific counseling for families making reproductive decisions. Monitor molecular diagnostics platforms at 1-minute intervals during business hours.
Clinical trial platforms protect enrollment windows for LCA gene-specific therapies. CEP290 antisense oligonucleotide trials, CRISPR editing studies, and GUCY2D-LCA gene therapy trials enrolling at specialized retinal dystrophy centers depend on platforms managing baseline ERG, FST, MLMT, and OCT data that establish the functional and anatomical endpoints against which post-treatment changes are measured, where data integrity failures at baseline assessment visits could invalidate a participant's endpoint comparisons and compromise the trial data that supports regulatory review of the next generation of LCA therapies. Monitor clinical trial platforms at 1-minute intervals during assessment visits.
Low vision and early intervention platforms support lifelong visual rehabilitation. LCA causes severe visual impairment from birth, making early intervention and ongoing low vision rehabilitation — orientation and mobility, white cane training, assistive technology for education and employment, braille literacy, and family support coordination — as central to LCA care as the emerging gene therapy pathway, where platform failures that interrupt early intervention scheduling, low vision device documentation, or specialized education coordination delay the skill-building that determines a child's educational and vocational trajectory independent of gene therapy outcomes. Monitor rehabilitation platforms during business and community hours.
What to Monitor on an LCA Tech Platform
Gene Therapy Eligibility Assessment
Monitor molecular confirmation platforms for biallelic RPE65 variant documentation, full-field ERG amplitude and implicit time measurement for eligibility threshold assessment, multi-luminance mobility testing (MLMT) scoring platforms with course-completion and accuracy documentation, full-field stimulus testing (FST) sensitivity measurement platforms, optical coherence tomography macular structure and photoreceptor layer thickness assessment, macular integrity grading documentation, specialist review and eligibility determination records, and FDA-required eligibility documentation generation at 1-minute intervals during clinical assessment sessions. Alert immediately — gene therapy eligibility assessment platform failures during an MLMT or FST session for an RPE65-LCA patient evaluating voretigene neparvovec eligibility delay the eligibility determination that gates access to the only FDA-approved gene therapy for a blinding inherited retinal dystrophy where photoreceptor preservation is a time-sensitive eligibility criterion.
Vitreoretinal Surgery and Subretinal Delivery
Monitor surgical planning records for bilateral sequential voretigene neparvovec subretinal injection (eye 1 and eye 2 operative scheduling, anesthesia records, surgical team credentialing documentation), investigational or commercial product chain of custody records for voretigene neparvovec, informed consent documentation, intraoperative OCT platform for subretinal bleb confirmation during subretinal injection, operative records including retinotomy site, bleb location, and vector distribution documentation, post-operative retinal examination records, and postoperative immunosuppression (oral prednisolone taper) administration records at 1-minute intervals during operative sessions. Alert immediately — surgical platform failures during an active subretinal voretigene neparvovec injection session for the first or second eye disrupt the operative documentation workflow at the most critical moment of an irreversible one-time gene therapy procedure where surgical and product custody documentation must be contemporaneous.
Molecular Genetics and LCA Gene Panel Diagnosis
Monitor next-generation sequencing panel platforms for LCA gene analysis (27-gene panel including deep intronic CEP290 variant detection), long-read sequencing or targeted assay platforms for CEP290 c.2991+1655A>G variant identification, structural variant analysis for CRB1 and other LCA genes, RNA functional analysis for splicing variants, variant classification and pathogenicity assessment documentation, gene therapy and clinical trial gene-eligibility matching records, genetic counseling session documentation, and cascade family member testing coordination at 1-minute intervals during business hours. Alert immediately — molecular diagnostics platform failures that delay RPE65 variant confirmation or CEP290 founder variant detection in a patient being evaluated for gene therapy or antisense oligonucleotide trial enrollment delay the eligibility determination that gates access to gene-specific treatment at a retinal dystrophy center where treatment timelines are constrained by preserving photoreceptor structure.
Retinal Structure and Function Longitudinal Monitoring
Monitor optical coherence tomography retinal thickness and photoreceptor layer mapping with longitudinal overlay comparison, fundus autofluorescence imaging for subretinal injection bleb boundary and post-treatment RPE response, adaptive optics scanning laser ophthalmoscopy (AOSLO) for photoreceptor cell density mapping in specialized centers, full-field and multifocal ERG recording and reporting, Goldmann kinetic perimetry and automated static perimetry, and color fundus photography at 1-minute intervals during clinical imaging sessions. Alert immediately — retinal monitoring platform failures during post-voretigene neparvovec treatment monitoring visits for an RPE65-LCA patient lose the ERG amplitude and OCT structural data at a scheduled post-treatment timepoint that is the primary evidence base for determining whether gene therapy has achieved its intended photoreceptor functional improvement.
Clinical Trial Enrollment and Safety Monitoring
Monitor CEP290 antisense oligonucleotide (sepofarsen) intravitreal injection administration and safety monitoring records, CRISPR subretinal editing study enrollment and procedure documentation, GUCY2D and other LCA gene therapy trial eligibility assessment and post-treatment monitoring, serious adverse event documentation, ophthalmic examination records for post-procedure inflammatory monitoring, data capture platform integrity for trial endpoints (ERG, FST, MLMT, BCVA, OCT), and regulatory submission coordination records at 1-minute intervals during assessment and treatment sessions. Alert immediately — clinical trial safety monitoring platform failures during the post-procedure inflammatory monitoring period for a CRISPR or gene therapy trial participant delay the adverse event detection and documentation that constitutes the primary safety endpoint for investigational retinal interventions where immune responses to viral vectors or edited cell products require early identification.
Low Vision, Early Intervention, and Pediatric Rehabilitation
Monitor early intervention records for infants and toddlers with LCA (vision developmental milestones, early intervention therapy records, family education documentation), low vision assessment records (visual acuity, contrast sensitivity, functional vision assessment for mobility), low vision device prescription records, orientation and mobility assessment and training records, braille literacy and tactile reading skill documentation, assistive technology records (screen magnifiers, refreshable braille displays, CCTV, screen readers), specialized education coordination records with schools for the blind or visually impaired, and occupational therapy records for activities of daily living at 1-minute intervals during clinical and community hours. Alert on sustained failures — rehabilitation platform unavailability delays the early intervention and low vision coordination that is the primary developmental support pathway for LCA children where visual rehabilitation and educational technology access are the durable long-term outcomes regardless of gene therapy eligibility.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. LCA programs coordinate across vitreoretinal surgery, pediatric ophthalmology, molecular genetics, low vision rehabilitation, early intervention, specialized education, and clinical trial administration — authentication failures simultaneously block every member of the multidisciplinary team managing a patient whose gene therapy eligibility assessment, surgical scheduling, molecular diagnostic reporting, and post-treatment monitoring all require continuous, coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, gene therapy eligibility assessment platforms, surgical planning systems, molecular diagnostics reporting platforms, clinical trial data capture systems, and early intervention and low vision rehabilitation portals. Certificate errors disrupt the eligibility assessment, surgical coordination, genetic reporting, trial enrollment, and rehabilitation documentation workflows of LCA management.
HIPAA and Genetic Privacy Considerations
LCA technology platforms handle sensitive PHI including molecular genetic testing identifying biallelic autosomal recessive pathogenic variants in LCA genes with direct reproductive implications for parents and siblings of affected children, gene therapy surgical records for subretinal voretigene neparvovec administration with investigational product chain of custody documentation, clinical trial participation records for CEP290 antisense oligonucleotide and CRISPR editing studies, pediatric early intervention records documenting severe visual impairment from infancy, specialized education records for children attending schools for the blind, low vision rehabilitation records documenting lifelong severe visual impairment, and post-treatment monitoring records documenting gene therapy response or non-response with profound personal and family significance. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing gene therapy eligibility assessment records where macular photoreceptor integrity measurement determines whether a child can receive voretigene neparvovec before degeneration eliminates the treatment window — and where that determination, combined with the molecular genetic results and surgical records, constitutes some of the most consequential health information a family will receive — privacy and availability standards must reflect the sensitivity of combined genomic, surgical, and early childhood developmental PHI managed across decades of care. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for LCA programs managing genetic, surgical, trial, and rehabilitative PHI from infancy through adulthood.
Alerting Strategy for LCA Tech Platforms
Immediate alerting during gene therapy eligibility assessment and surgical sessions: MLMT, FST, OCT macular integrity, ERG amplitude platforms during eligibility assessment appointments; subretinal injection operative documentation and intraoperative OCT platforms during surgery. These cannot fail without direct eligibility determination and surgical documentation consequences.
Immediate alerting during clinical trial assessment visits: CEP290 antisense oligonucleotide and CRISPR study safety monitoring, ERG and OCT endpoint data capture, and adverse event documentation platforms during post-procedure monitoring visits.
Immediate business-hours alert: Molecular diagnostics and LCA gene panel reporting, variant classification, gene therapy eligibility matching, and genetic counseling documentation platforms. Alert the moment these fail during active reporting or counseling encounters.
Sustained-failure alert (10–15 minutes): Low vision rehabilitation documentation, early intervention scheduling, specialized education coordination, orientation and mobility records, and post-treatment surveillance scheduling platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms LCA platform availability from the geographies where RPE65-LCA gene therapy centers, retinal dystrophy programs with CEP290 trial access, and pediatric low vision centers concentrate — important for a condition where gene therapy access is limited to a relatively small number of certified centers and where families travel significant distances for eligibility evaluation and surgical treatment.
Status Page for LCA Care Team Communication
A real-time status page gives vitreoretinal surgeons managing voretigene neparvovec subretinal injection, retinal dystrophy specialists conducting MLMT and FST eligibility assessments, molecular geneticists reporting LCA gene panel variants and gene therapy eligibility matching, clinical trial coordinators managing CEP290 antisense oligonucleotide and CRISPR study safety monitoring, early intervention specialists and low vision therapists coordinating pediatric visual rehabilitation, and specialized education liaisons immediate platform visibility without requiring inbound IT support contact. During a gene therapy eligibility assessment platform outage at the scheduled MLMT assessment appointment for an RPE65-LCA child whose family has traveled for gene therapy evaluation, a status page enables the retinal dystrophy coordinator to immediately communicate the outage status, activate the contingency rescheduling protocol, and notify the family of the revised assessment timeline before they leave the center.
Include the status page URL in gene therapy eligibility assessment downtime procedures, vitreoretinal surgical emergency documentation workflows, molecular genetics laboratory emergency access protocols, clinical trial contingency assessment procedures, and early intervention scheduling emergency fallback procedures.
Vigilmon Setup for LCA Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Gene therapy eligibility: MLMT, FST, OCT macular integrity, ERG | 1 min | Slack + PagerDuty (clinical hours) | | Subretinal injection operative documentation and intraoperative OCT | 1 min | Slack + PagerDuty (operative hours) | | LCA molecular diagnostics and variant classification (27-gene panel) | 1 min | Slack + PagerDuty (business hours) | | CEP290 antisense oligonucleotide / CRISPR trial safety monitoring | 1 min | Slack + PagerDuty (assessment hours) | | Post-voretigene ERG, OCT, and post-treatment monitoring | 1 min | Slack + PagerDuty (clinical hours) | | Fundus autofluorescence and adaptive optics imaging | 1 min | Slack + PagerDuty (imaging hours) | | Early intervention and pediatric visual rehabilitation | 2 min | Slack (business hours) | | Low vision assessment and device documentation | 2 min | Slack (business hours) | | Specialized education coordination and orientation & mobility | 2 min | Slack (business hours) | | Patient and family communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure MLMT, FST, OCT macular integrity, and ERG eligibility assessment platforms with immediate alerting during clinical hours
- Add subretinal injection operative documentation and intraoperative OCT with immediate alerting during operative sessions
- Configure LCA molecular diagnostics and 27-gene panel variant classification with immediate business-hours alerting
- Add CEP290 antisense oligonucleotide and CRISPR trial safety monitoring with immediate assessment-hours alerting
- Configure post-voretigene ERG, OCT, and post-treatment structural monitoring with immediate alerting during clinical hours
- Add fundus autofluorescence and adaptive optics imaging with immediate alerting during imaging sessions
- Configure early intervention and pediatric visual rehabilitation with sustained-failure alerting
- Add low vision assessment, device documentation, and orientation and mobility records with sustained-failure alerting
- Configure specialized education coordination and communication support with sustained-failure alerting
- Enable SSL certificate monitoring across all gene therapy, surgical, molecular diagnostics, trial, and rehabilitation domains
- Add the status page URL to gene therapy eligibility downtime procedures, surgical emergency documentation workflows, and clinical trial contingency protocols
Conclusion
LCA technology platforms are embedded in clinical decisions where gene therapy eligibility assessment platform availability during the scheduled multi-luminance mobility testing and full-field stimulus testing session for a seven-year-old with RPE65-LCA — where the low vision specialist administering the MLMT course under defined luminance levels from 400 lux to 1 lux and recording navigation accuracy and speed at each luminance level that constitutes the primary functional eligibility criterion for voretigene neparvovec, where the electrophysiologist recording the full-field ERG amplitude that must meet the minimum threshold for detectable residual photoreceptor function, where the retinal imaging specialist acquiring the macular OCT confirming viable photoreceptor cell layer thickness in the foveal region that is the structural eligibility criterion, and where the specialist reviewing all three data streams to complete the FDA-required eligibility documentation that must be filed before the surgical scheduling window — must all be available simultaneously on a platform that is being used for a single irreplaceable eligibility assessment visit that families may have traveled across the country to attend and whose results determine whether a child receives the only FDA-approved treatment for their blinding condition before progressive photoreceptor degeneration eliminates the structural eligibility criterion; where vitreoretinal surgical platform availability during the subretinal voretigene neparvovec injection into the second eye — where the operative documentation system records the pars plana vitrectomy approach, the subretinal bleb formation confirmed by intraoperative OCT, the retinotomy site coordinates, the 0.3 mL delivery volume and injection time, and the chain of custody records for the investigational product from cold-chain storage to subretinal delivery, where a contemporaneous surgical record is required both for the patient's medical record and for the product's pharmacovigilance documentation, and where failure to save the operative record at the time of surgery creates a documentation gap in a one-time irreversible gene therapy procedure — determines whether the second-eye surgical record is complete; where molecular diagnostics platform availability when the molecular geneticist is finalizing the variant classification for a child's CEP290 intronic variant — where the RNA splicing assay result confirming exon skipping from the c.2991+1655A>G variant reclassifies the variant from uncertain significance to pathogenic, enabling the family to be counseled about CEP290-specific antisense oligonucleotide trial eligibility and the child's name to be submitted to the trial coordinating center before the enrollment cohort closes — cannot be delayed by platform unavailability at the moment the classification is ready to be issued; and where early intervention platform availability for the monthly developmental assessment visit for a two-year-old with CRB1-LCA — where the early intervention specialist documenting tactile exploration milestones, the orientation and mobility instructor documenting early cane orientation skills, and the vision teacher of students with visual impairments documenting object permanence and reach-and-locate skills that together constitute the developmental record the specialized education team needs for the upcoming IEP review — must access the early intervention platform during the home visit where contemporaneous documentation is standard practice: an MLMT platform that fails when the clinical coordinator has completed the first three luminance levels but the platform crashes before the lowest luminance levels are completed and the session cannot be resumed that day, a surgical documentation system inaccessible when the vitreoretinal surgeon needs to complete the operative note for the second-eye voretigene neparvovec injection, a genetics reporting platform unavailable when the molecular geneticist is ready to issue the CEP290 reclassification that enables antisense oligonucleotide trial enrollment, an early intervention documentation platform down when the vision specialist is recording the developmental assessment that forms the evidentiary basis for the IEP — these are not IT incidents. They are disruptions in the care of children with the most severe inherited retinal dystrophy for whom the convergence of FDA-approved gene therapy, active clinical trials, and intensive early childhood rehabilitation has created a care environment where platform availability at every assessment, surgical, diagnostic, and rehabilitation touchpoint directly determines outcomes in a condition where the treatment window is measured not in months but in the irreversible progression of photoreceptor degeneration.
Uptime monitoring gives LCA tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to vitreoretinal surgery programs, retinal dystrophy centers, molecular genetics laboratories, clinical trial coordinating centers, and compliance auditors that platform operational reliability matches the gene therapy, surgical, molecular diagnostic, and rehabilitative complexity of modern LCA care.
Start monitoring your LCA care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #LeberCongenitalAmaurosis #LCA #RPE65 #CEP290 #voretigeneNeparvovec #Luxturna #geneTherapy #subretinalInjection #inheritedRetinalDystrophy #electroretinography #OCT #MLMT #FST #lowvision #pediatricOphthalmology #HIPAA #raredisease #healthtech #digitalhealth #uptime #sre